www.canfite.com Open in urlscan Pro
82.163.249.48  Public Scan

Form analysis
1 forms found in the DOM

POST #

<form id="searchForm" class="right-rtl" action="#" method="post">
  <div class="input-group wcag-dynamic-font" data-wcag-org-font-size="16">
    <input type="text" class="form-control right-rtl wcag-dynamic-font" name="q" id="q" required="" aria-label="Search" placeholder="Search" data-msg-required="please enter search value" data-wcag-org-font-size="13.6">
    <span class="input-group-btn wcag-dynamic-font" data-wcag-org-font-size="16">
      <button class="btn btn-default btn-custom" type="submit" title="Search" role="button"><i class="fa fa-search fa-flip-horizontal wcag-dynamic-font" data-wcag-org-font-size="16"></i></button>
    </span>
  </div>
</form>

Text Content

Skip to Main Content
 * Font Size A+ A- Default Size
 * Match Impaired People
 * Match Color-Blinded People
 * Hide animations
 * Default Display
 * Accessibility Menu Language עברית English русский العربية
 * Accessibility Statement
 * Contact
 * Close
 * Sense Force הנגשת אתרים

 * ABOUT
   * Overview
   * Management
   * Drug Development Team
   * Board of Directors
   * Corporate Partnerships
 * SCIENCE
   * Technology Platform
   * Scientific Publications
 * PIPELINE
   * Overview
   * Piclidenoson (CF101)
   * Namodenoson (CF102)
   * CF602
   * Cannabinoids
 * INVESTORS
   * Overview
   * News & Events
   * Company Information
   * Financial Information
   * Stock Information
   * SEC Fillings
   * Corporate Governance
   * Shareholders Meetings
 * CONTACT

Menu
×

 * Small Molecules
   for Big Clinical NeedsTMOral drugs with proven safety and efficacy
 * Small Molecules
   for Big Clinical NeedsTMOral drugs with proven safety and efficacy
 * Small Molecules
   for Big Clinical NeedsTMOral drugs with proven safety and efficacy






ABOUT US


CAN·FITE BIOPHARMA

is an Israeli biopharmaceutical company with fully integrated pharmaceutical
discovery and clinical development capabilities.


The Company has an advanced pipeline of proprietary drug candidates in Phase II
and Phase III clinical development which address inflammatory, liver and
metabolic diseases.


Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine
receptor (A3AR) as a therapeutic target. A3AR is highly expressed in
inflammatory, cancer and other pathological body cells whereas low expression is
found in normal cells, suggesting that the receptor could be a unique target for
pharmacological intervention.


The Company's compounds bind with nM affinity to the A3AR and initiate
de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in
anti-inflammatory and anti-cancer effects.

LEARN MORE



PRESS RELEASES


VIEW MORE


PIPELINE



--------------------------------------------------------------------------------


CORPORATE PARTNERSHIPS

Piclidenoson for the treatment of psoriasis has been out-licensed to Cipher
Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,
Kyongbo Pharm in Korea, to CMS  in China, Taiwan, Hong Kong and Macao.

Namodenoson for the treatment of Liver Cancer and NASH has been out-licensed  to
Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.

You have reached the bottom of the page - Go to Top
 * HOME
 * CONTACT

© 2021 Can-Fite All Rights Reserved

 * 
 * 

BRANDWIZ - עיצוב גרפי

 | עיצוב ובניית אתרים

 | מיתוג עסקי



arrow You have reached the bottom of the page - Go to Top